These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7961092)

  • 1. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
    Ogilvie GK; Moore AS; Chen C; Ciekot PA; Atwater SW; Bergman PJ; Walters LM
    J Am Vet Med Assoc; 1994 Aug; 205(4):570-3. PubMed ID: 7961092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
    Ogilvie GK; Obradovich JE; Elmslie RE; Vail DM; Moore AS; Curtis CR; Straw RC; Dickinson K; Cooper MF; Withrow SJ
    J Am Vet Med Assoc; 1991 May; 198(9):1613-7. PubMed ID: 2061176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
    Ogilvie GK; Moore AS; Obradovich JE; Elmslie RE; Vail DM; Straw RC; Salmon MD; Klein MK; Atwater SW; Ciekot PE
    J Am Vet Med Assoc; 1993 Jun; 202(11):1839-44. PubMed ID: 8320152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
    Ogilvie GK; Richardson RC; Curtis CR; Withrow SJ; Reynolds HA; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
    J Am Vet Med Assoc; 1989 Dec; 195(11):1584-7. PubMed ID: 2599942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of mitoxantrone against various neoplasms in dogs.
    Ogilvie GK; Obradovich JE; Elmslie RE; Vail DM; Moore AS; Straw RC; Dickinson K; Cooper MF; Withrow SJ
    J Am Vet Med Assoc; 1991 May; 198(9):1618-21. PubMed ID: 2061177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
    Moore AS; Ogilvie GK; Ruslander D; Rand WS; Cotter SM; Getzy DM; L'Heureux DA; Dennis RA
    J Am Vet Med Assoc; 1994 Jun; 204(12):1903-5. PubMed ID: 8077132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.
    Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K
    J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cisplatin-induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987).
    Ogilvie GK; Moore AS; Curtis CR
    J Am Vet Med Assoc; 1989 Nov; 195(10):1399-403. PubMed ID: 2584105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of doxorubicin for treatment of various canine neoplasms.
    Ogilvie GK; Reynolds HA; Richardson RC; Withrow SJ; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
    J Am Vet Med Assoc; 1989 Dec; 195(11):1580-3. PubMed ID: 2599941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989).
    Ogilvie GK; Straw RC; Powers BE; Cooper MF; Withrow SJ
    J Am Vet Med Assoc; 1991 Sep; 199(5):613-6. PubMed ID: 1787122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991).
    Ogilvie GK; Straw RC; Jameson VJ; Walters LM; Lafferty MH; Powers BE; Withrow SJ
    J Am Vet Med Assoc; 1993 Jan; 202(2):304-6. PubMed ID: 8428842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
    Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
    J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant canine granulocyte colony-stimulating factor to decrease myelosuppression associated with the administration of mitoxantrone in the dog.
    Ogilvie GK; Obradovich JE; Cooper MF; Walters LM; Salman MD; Boone TC
    J Vet Intern Med; 1992; 6(1):44-7. PubMed ID: 1372355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia.
    Moore AS; Ruslander D; Cotter SM; Rand WM; L'Heureux DA
    J Am Vet Med Assoc; 1995 May; 206(10):1550-4. PubMed ID: 7775231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
    Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
    J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a one-hour saline diuresis protocol for administration of cisplatin to dogs.
    Ogilvie GK; Fettman MJ; Jameson VJ; Walters LM; Lafferty MH; Cooper MF; Powers BE; Ciekot PA; Atwater SW; Withrow SJ
    Am J Vet Res; 1992 Sep; 53(9):1666-9. PubMed ID: 1416374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs.
    Arrington KA; Legendre AM; Tabeling GS; Frazier DL
    Am J Vet Res; 1994 Nov; 55(11):1587-92. PubMed ID: 7879983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a biological extract of Serratia marcescens to decrease doxorubicin-induced myelosuppression in dogs.
    Ogilvie GK; Elmslie RE; Cecchini M; Walters LM; Pearson FC
    Am J Vet Res; 1992 Oct; 53(10):1787-90. PubMed ID: 1280926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
    Upton ML; Tangner CH; Payton ME
    J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.